Effect of intratympanic dexamethasone injection in sudden idiopathic sensorineural hearing loss
DOI:
https://doi.org/10.18203/issn.2454-5929.ijohns20163477Keywords:
Intratympanic dexamethasone, Sudden sensorineural hearing lossAbstract
Background: The aim of this study is to assess the effect of intratympanic dexamethasone injection (ITDI) in patients with idiopathic sudden sensorineural hearing loss (ISSNHL).
Methods: A prospective study was conducted on 40 patients refractory to intravenous steroid therapy between May 2012 to March 2014. Intratympanic dexamethasone injection was given every week for 3 consecutive weeks. Hearing was assessed by performing pure tone audiogram before every ITDI and also 1 week after the completion of treatment.
Results: Hearing improvement was seen in 27 out of the 40 cases (68%).
Conclusions: Intratympanic dexamethasone significantly improves the prognosis of ISSNHL and is a safe, inexpensive and effective treatment in ISSNHL.
References
Rauch SD. Idiopathic sudden sensorineural hearing loss. New England Journal of Medicine. 2008;359(8):788–840.
Wilson WR, Byl FM, Laird N. The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A doubleblind clinical study. Archives of Otolaryngology.1980;106(12):772–6.
Chen CY, Halpin C, Rauch CH. Oral steroid treatment of Sudden Sensorineural Hearing Loss: a ten year retrospective analysis. Otology and Neurotology. 2003;24(5):728–33.
Conlin AE, Parnes LS. Treatment of sudden sensorineural hearing loss II. A meta-analysis. Archives of Otolaryngology. 2007;133(6):582–6.
Guan-Min H, Hung-Ching L, Min-Tsan S, Cheng-Chien Y, Hsun-TienT. Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope. 2004;114(7):1184–9.
Haynes DS, Malley MO, Cohen S, Watford K, Labadie RF. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope. 2007;117(1):3–15.
Plaza G, Herraiz H. Intratympanic steroids for treatment of sudden hearing loss after failure of intravenous therapy. Otolaryngology. 2007;137(1):74–8.
Fitzgerald DS, McGuire JF. Intratympanic steroids for idiopathic sudden sensorineural hearing loss. Annals of Otology, Rhinology and Laryngology. 2007;116(4):253-6.
Slattery WH, Fisher LM, Iqbal Z, Friedman RA, Liu N. Intratympanic steroid injection for treatment of idiopathic sudden hearing loss. Otolaryngology. 2005;133(2):251-9.
Chandrasekhar SS. Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation. Otology and Neurotology. 2001;22(1):18-23.
Gianoli GJ, Li JC. Transtympanic steroids for treatment of sudden hearing loss. Otolaryngology. 2001;125(3):142-6.
Battaglia A, Burchette R, Cueva R. Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otology and Neurotology. 2008;29(4):4.
Choung YH, Park K, Shin YR, Cho MJ. Intratympanic dexamethasone injection for refractory sudden sensorineural hearing loss. Laryngoscope. 2006;116(5):747-52.
Mattox DE, Simmons FB. Natural history of sudden sensorineural hearing loss. Annals of Otology, Rhinology and Laryngology. 1977;86(4):463-80.
Cinamon U, Bendet E, Kronenberg J. Steroids, carbogen or placebo for sudden hearing loss: a prospective double-blind study. European Archives of Oto-Rhino-Laryngology. 2001;258(9):477-80.
Parnes LS, Sun AH, Freeman DJ. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope. 1999;109(7)1-17.
Hamid M, Trune D. Issues, indications and controversies regarding intratympanic steroid perfusion. Current Opinion in Otolaryngology and Head and Neck Surgery. 2008;16(5):434-40.
Kitahara T, Fukushima M, Uno Y, Mishiro Y, Kubo T. Upregulation of cochlear aquaporin-3 mRNA expression after intra-endolymphatic application of dexamethasone. Neurological Research. 2003;25(8):865-70.
Trune DR, Kempton JB, Harrison AR, Wobig JL. Glucocorticoid impact on cochlear function and systemic side effects in autoimmune C3. MRL-Faslpr and normal C3H/Hej mice. Hearing Research. 2007;226(1):209-17.